Showing 41-50 of 143 results for "".
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuLaser hair removal in darker skin types, challenges and technological advances for treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-hair-removal-in-darker-skin-types-challenges-and-technological-advances-for-treatment/18800/Andrew Alexis, MD discusses laser hair removal treatment challenges in patients with higher Fitzpatrick skin types, and how recent advances in technology have been able to address these to deliver effective treatment with minimal pain.Make a Profound Impact
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/make-a-profound-impact/18886/Macrene Alexiades, MD, Ph.D, shares her experience with the Profound system, a micro-needling RF device, with real-time temperature feedback mechanism that improves mandibular and submandibular contouring. The device works by stimulating collagen, elastin and hyaluronic acid resulting in a youthfulNew eRelevance Services, Cosmetic Bootcamp Updates, Leo & AID Partnership
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-new-erelevance-services-cosmetic-bootcamp-updates-leo-aid-partnership/18291/eRelevance has launched a suite of 4 services intended to support aesthetic practices in optimizing their marketing strategies to capture, convert, and retain patients. CEO Bob Fabbio discusses. Aesthetic education takes center stage at Cosmetic Boot Camp in Aspen. The meeting is open only to boardJournal Club: Tapinarof Cream in Pediatric Patients
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-tapinarof-cream-in-pediatric-patients/32399/Practical Dermatology Editorial Board member Peter Lio, MD, speaks with Mona Shahriari, MD, about the Journal of Dermatology article "A phase 2, randomized, double-blind, vehicle-controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis," and the general importance ofDermWireTV: Arcutis Survey on PsO Impact; Tinted Sunscreen Update; Cosmetic Interventions and Illness; Dr. Seemal Desai Elected
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-arcutis-survey-on-pso-impact-tinted-sunscreen-update-cosmetic-interventions-and-illness-dr-seema-desai-elected/20089/Arcutis Biotherapeutics' survey finds Individuals with psoriasis who use topical treatments want more effective and simpler interventions. Intertriginous disease poses particular challenges. Increased availability of tinted sunscreens could increase the use of SPF among individuals with darker skinDermWireTV 09.12.19: Otezla to Amgen, A Juvéderm First, Skin Cancer Foundation News
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-091219-otezla-to-amgen-a-juvederm-first-skin-cancer-foundation-news/19663/After traveling more than 10,000 miles across the US, the Skin Cancer Foundation’s “Destination: Healthy Skin” Program is wrapping up for the season. Plus, the Champions for Change Gala is coming October 17. Amgen has entered into an agreement with Celgene Corporation Company to acquire worldwide riEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, and- Syneron Candela Achieves Approval to Market Its ALEX II System in Japanhttps://practicaldermatology.com/news/20140429-syneron_candela_achieves_approval_to_market_its_alex_ii_system_in_japan/2459250/Syneron Medical Ltd.'s subsidiary in Japan, Candela KK, received registration approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its ALEX II system in Japan for the treatment of benign dermal lesions.&nbs
- Study: R&R Complex Superior to Ceramide Moisturizer for Dermatoporosishttps://practicaldermatology.com/news/study-rr-complex-superior-ceramide-moisturizer-dermatoporosis/2468413/Results from a split-arm study suggest that use of a new product (ReFORM & RePAIR COMPLEX with TriHex Technology® [R&R]) resulted in more skin improvements than a ceramide moisturizer in patients with dermatoporosis (DP). Conducted over 24 weeks, the trial included 38 participants